1
|
Alkhayat N, Alshahrani M, Elyamany G, Sedick Q, Ibrahim W, Hamzi H, Binhassan A, Othman M, Alshieban S, Aljabry MS, Asiri S, Alzouman M, Alsuhaibani O, Alabbas F, Alsharif O, Elborai Y. Clinicopathologic features and therapy outcome in childhood Hodgkin's lymphoma: a report from tertiary care center in Saudi Arabia. J Egypt Natl Canc Inst 2021; 33:21. [PMID: 34396456 DOI: 10.1186/s43046-021-00078-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2020] [Accepted: 07/18/2021] [Indexed: 12/22/2022] Open
Abstract
BACKGROUND Hodgkin lymphoma (HL) is lymphoid neoplasm usually affecting lymphatic system; it accounts 3.6% of cancers in Saudi Arabia. Modern treatment protocols had shown particular success rates in overall-survival (OS) and event-free-survival (EFS). In our study, we reviewed the medical records of 80 pediatric and young adolescent patients diagnosed HL from January 2006 to July 2020, treated at tertiary care hospital in Riyadh, Saudi Arabia. Demographic, clinical, and pathological data were explored. First line therapy was ABVD, COG, COPP, R-CHOP, or radiotherapy alone in 53/80 (66.4%), 24/80 (30%), 1/80 (1.2%), 1/80 (1.2%), or 1/80 (1.2%) patients; respectively. Response assessment was done by CT + / - PET scan after first 2 cycles then every 2 cycle and end of therapy. Another assessment was done if any clinical suspicion of recurrence. RESULTS Median age 11 (range 3-16) years. Males to females 1.3:1. Seventy-two out of eighty (90%) patients showed first complete remission (CR1) and maintained remission for median 40 (range 7-136) months. Eight out of eighty (10%) patients showed refractory disease. Nineteen patients received salvage therapy (ICE or ESHAP/brentuximab vedotin or gemcitabine/brentuximab vedotin), 14/19 (73.7%) had 2nd complete remission (CR2) for median time 24 (ranged 9-78) months, while 5/19 (26.3%) did not show any response. Five-year OS and EFS were 95% and 75%. Two patients had 2ry malignant neoplasms, one had AML and died, the other had malignant fibrous histocytoma and still alive. None of our patients had fertility problem. Also, they did not experience chronic pulmonary or cardiotoxicity. Classic Hodgkin's lymphoma: nodular sclerosis subtype was more prominent (55%) than mixed cellularity subtype (22.5%), which is similar to several European and US studies, lymphocyte rich (11.25%) and lymphocyte depleted (0%), while nodular lymphocyte predominant Hodgkin's lymphoma (11.25%). CONCLUSIONS Our study provided unique descriptive study of childhood HL, in Saudi Arabia, with valuable insight into the long-term outcome and late toxicity. Our results are comparable to other studies in the Middle East and European countries.
Collapse
Affiliation(s)
- Nawaf Alkhayat
- Department of Pediatric Hematology/Oncology, Prince Sultan Military Medical City, Riyadh, Riyadh, 11159, Saudi Arabia
| | - Mohammad Alshahrani
- Department of Pediatric Hematology/Oncology, Prince Sultan Military Medical City, Riyadh, Riyadh, 11159, Saudi Arabia.
| | - Ghaleb Elyamany
- Department of Central Military Laboratory and Blood Bank, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
| | - Qanita Sedick
- Department of Central Military Laboratory and Blood Bank, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
| | - Walid Ibrahim
- Department of Pediatric Hematology/Oncology, Prince Sultan Military Medical City, Riyadh, Riyadh, 11159, Saudi Arabia
| | - Hasna Hamzi
- Department of Pediatric Hematology/Oncology, Prince Sultan Military Medical City, Riyadh, Riyadh, 11159, Saudi Arabia
| | - Amal Binhassan
- Department of Pediatric Hematology/Oncology, Prince Sultan Military Medical City, Riyadh, Riyadh, 11159, Saudi Arabia
| | - Mohamed Othman
- Department of Pediatric Hematology/Oncology, Prince Sultan Military Medical City, Riyadh, Riyadh, 11159, Saudi Arabia
| | - Saeed Alshieban
- Department of Pathology and Laboratory Medicine, Ministry of National Guard Health Affairs, King Abdullah International Medical Research Center, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
| | - Mansour S Aljabry
- Pathology Department, King Khalid University Hospital, King Saud University, Riyadh, Kingdom of Saudi Arabia
| | - Shuaa Asiri
- Department of Central Military Laboratory and Blood Bank, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
| | - Muneerah Alzouman
- Department of Central Military Laboratory and Blood Bank, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
| | - Omar Alsuhaibani
- Department of Central Military Laboratory and Blood Bank, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
| | - Fahad Alabbas
- Department of Pediatric Hematology/Oncology, Prince Sultan Military Medical City, Riyadh, Riyadh, 11159, Saudi Arabia
| | - Omar Alsharif
- Department of Pediatric Hematology/Oncology, Prince Sultan Military Medical City, Riyadh, Riyadh, 11159, Saudi Arabia
| | - Yasser Elborai
- Department of Pediatric Oncology, National Cancer Institute, Cairo University, Cairo, Egypt
| |
Collapse
|